|
March
9, 2007--Jazz
Pharmaceuticals (Palo Alto, CA) filed for a $172.5 million
IPO. Jazz, which focuses on developing products for
neurology and psychiatry medical needs, reported a net
loss of $59.4 million on $44.9 million total revenues in
2006, compared with a $85.2 million net loss on $21.4
million in total revenues in 2005. Reuters |
